• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[甲状腺毒症中的骨骼变化]

[Bone changes in thyrotoxicosis].

作者信息

Ejima E, Fujiyama K, Kiriyama T, Eguchi K

机构信息

First Department of Internal Medicine, Nagasaki University School of Medicine.

出版信息

Nihon Rinsho. 1998 Jun;56(6):1587-90.

PMID:9648486
Abstract

Thyroid hormone (T3) is essential for normal bone growth and bone metabolism. T3 stimulates bone formation directly through T3 receptors in osteoblasts. T3 also stimulates bone resorption by osteoclasts probably secondary through osteoblasts. In thyrotoxicosis accelerated bone formation and resorption resulted in high turn-over bone loss. Bone metabolic markers elevate reflecting thyrotoxic state. Normalizing thyroid hormone level at least partially restore bone mineral content. In patients under thyroid hormone replacement therapy or TSH suppression therapy TSH and free thyroid hormones should be monitored to prevent unnecessary bone loss. Especially in postmenopausal women with thyrotoxicosis or thyroid hormone therapy the assessment of bone mineral content is required.

摘要

甲状腺激素(T3)对正常骨骼生长和骨代谢至关重要。T3通过成骨细胞中的T3受体直接刺激骨形成。T3还可能通过成骨细胞间接刺激破骨细胞的骨吸收。在甲状腺毒症中,加速的骨形成和吸收导致高转换型骨质流失。骨代谢标志物升高反映甲状腺毒症状态。使甲状腺激素水平正常化至少可部分恢复骨矿物质含量。在接受甲状腺激素替代治疗或促甲状腺激素抑制治疗的患者中,应监测促甲状腺激素和游离甲状腺激素,以防止不必要的骨质流失。特别是在患有甲状腺毒症或接受甲状腺激素治疗的绝经后女性中,需要评估骨矿物质含量。

相似文献

1
[Bone changes in thyrotoxicosis].[甲状腺毒症中的骨骼变化]
Nihon Rinsho. 1998 Jun;56(6):1587-90.
2
[Osteoporosis treatment in patients with hyperthyroidism].[甲状腺功能亢进症患者的骨质疏松症治疗]
Nihon Rinsho. 2009 May;67(5):1011-6.
3
[The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis].[甲状腺毒症及甲状腺素治疗对骨质疏松症风险的影响]
Pol Merkur Lekarski. 2000 May;8(47):356-9.
4
Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?在原发性骨质疏松症或雌激素替代治疗后,骨骼对甲状腺激素的反应性是否会发生改变?
J Bone Miner Res. 1997 Jan;12(1):78-88. doi: 10.1359/jbmr.1997.12.1.78.
5
Paradigm shift in the pathophysiology of postmenopausal and thyrotoxic osteoporosis.绝经后骨质疏松症和甲状腺毒症性骨质疏松症病理生理学的范式转变。
Mt Sinai J Med. 2009 Oct;76(5):474-83. doi: 10.1002/msj.20136.
6
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.重组人促甲状腺激素可调节绝经后妇女体内I型胶原C端肽和骨碱性磷酸酶水平,但对监测分化型甲状腺癌的绝经后妇女骨保护素的产生无影响。
J Bone Miner Res. 2005 Mar;20(3):480-6. doi: 10.1359/JBMR.041126. Epub 2004 Nov 29.
7
[The risk for osteoporosis in persons treated with thyroid hormones].[接受甲状腺激素治疗的人群患骨质疏松症的风险]
Vnitr Lek. 1992 Sep;38(9):860-7.
8
[Graves' disease and bone metabolism].[格雷夫斯病与骨代谢]
Nihon Rinsho. 2006 Dec;64(12):2317-22.
9
Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.生长激素短期治疗可刺激骨质减少的绝经后女性的成骨细胞和破骨细胞活性:一项剂量反应研究。
J Bone Miner Res. 1995 Dec;10(12):1865-74. doi: 10.1002/jbmr.5650101205.
10
Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.绝经后脊柱骨质疏松症患者对外源性生长激素的正常破骨细胞和成骨细胞反应。
J Bone Miner Res. 1994 Sep;9(9):1365-70. doi: 10.1002/jbmr.5650090907.

引用本文的文献

1
Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.肥大细胞的基因变化及其在肥大细胞瘤预后和治疗中的意义。
Genes (Basel). 2024 Jan 22;15(1):137. doi: 10.3390/genes15010137.
2
Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study.2型糖尿病患者的甲状腺与骨转换标志物:METAL研究结果
Endocr Connect. 2022 Mar 31;11(3):e210484. doi: 10.1530/EC-21-0484.